Results 121 to 130 of about 84,496 (265)
Hemostatic rescue with rFVIIa in Bernard-Soulier syndrome refractory to HLA-matched platelet transfusion. [PDF]
Okamoto Y +6 more
europepmc +1 more source
Summary Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital.
Allison Mo +15 more
wiley +1 more source
Patient Blood Management in Hematology: Focusing on Platelet Transfusion. [PDF]
Solves P +7 more
europepmc +1 more source
Summary Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition associated with severe fetal thrombocytopenia and intracerebral haemorrhage. Antenatal management of subsequent pregnancies relies on intravenous immunoglobulin (IVIg); yet, practice varies internationally and UK data are limited.
Asha Aggarwal +8 more
wiley +1 more source
Platelet transfusion practice in the intensive care unit: the Nine-I international platelet transfusion survey. [PDF]
Russell L +25 more
europepmc +1 more source
Abnormal neutrophils and platelets in splenectomised β‐thalassaemia/haemoglobin E (HbE) disease contribute to neutrophil–platelet aggregation, leading to a high risk of thrombus formation. Activated platelets induce neutrophils to generate neutrophil extracellular trap (NETs) via the P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) pathway, which ...
Rattanawan Thubthed +11 more
wiley +1 more source
Postresuscitation platelet transfusion in major trauma patients. [PDF]
Rossetto A +5 more
europepmc +1 more source
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall +14 more
wiley +1 more source
Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden +3 more
wiley +1 more source

